Skip Navigation

European Heart Journal 1992 13(6):808-813;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by KULAKOWSKI, P.
Right arrow Articles by CAMM, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KULAKOWSKI, P.
Right arrow Articles by CAMM, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Flecainide-related alterations in the signal-averaged electrocardiogram: similarity between patients with or without ventricular tachycardia

P. KULAKOWSKI*,, S. GIBSON, J. WARD and A. J. CAMM

Department of Cardiological Sciences, St George's Hospital Medical School London, U.K.
*Dr Kulakowski of Ilnd Department of Cardiology, Medical Centre of Postgraduate Education, Warsaw, Poland is currently supported by a research fellowship from the European Society of Cardiology

Received 25 January 1991; revised 7 May 1991; .

Correspondence: Piotr Kulakowski, MD, Department of Cardiological Sciences, Si George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, U.K.

Abstract

The signal-averaged electrocardiogram (SAECG) identifies patients at risk of sustained ventricular tachycardia (VT), but the influence of anti-arrhythmic agents on the SAECG is not yet established. We have evaluated the effects of flecainide on the SAECG (XYZ leads, high-pass filters 25 Hz and 40 Hz, noise level 0.2 µV-0.4 µV, Model 1200 EPX, ART) in 25 patients: 15 (VT group) had documented sustained VT (ninepost-MI, two dilated cardiomyopathy, four normal hearts) and 10 (control group) had supraventricular arrhythmias and structurally normal hearts. The SAECG was recorded in all patients prior to, and 5 min following a flecainide infusion (2 mg. kg–1 over 10 min).

Before flecainide administration an abnormal SA ECG was recorded in six patients from the VT group and in no control patient. Following flecainide, 13 patients from the VT group and eight control subjects demonstrated abnormal SAECG. Flecainide produced similar significant percentage changes in all SA ECG indices in both the VT and control groups: total QRS duration was prolonged by 26.0±10.4% vs 26.7± 15.7%, late potential duration under 40 µV was prolonged by 55.5±62.0% vs 106.1 ±61.4%, and the root mean square voltage of the last 40ms of the QRS was reduced by 42.1 ± 34.9% vs 55.3 ± 24.4%, respectively.

We conclude that flecainide significantly changes the SAECG parameters in patients with and without a history of VT, irrespective of the underlying disease.

Key Words: Signal-averaged electrocardiogram • flecainide • ventricular tachycardia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.